The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...
Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback